HomeFilePharmacology

Pharmacology

View Category

Antiplatelet

Cangrelor in Acute and Chronic Coronary Syndromes: The POMPEII Registry

Platelet inhibition during and after coronary angioplasty is essential to prevent peri- and post-procedural ischemic events. To...
Dr. Omar Tupayachi -
Learn More
Acute coronary syndromes

Pretreatment with DAPT in Acute Coronary Syndrome: An Ongoing Debate?

In acute coronary syndrome (ACS) dual antiplatelet therapy (DAPT) has become a fundamental pillar after percutaneous coronary...
Dr. Omar Tupayachi -
Learn More
Antiplatelet

SMART-CHOICE 3 | Efficacy and Safety of Clopidogrel vs Aspirin Monotherapy in High Risk Patients after Percutaneous Coronary Intervention

Courtesy of Dr. Juan Manuel Pérez. After post percutaneous coronary intervention (PCI) standard duration dual antiplatelet therapy (DAPT),...
Dr. Juan Manuel Pérez -
Learn More
Antiplatelet

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a...
Dr. Andrés Rodríguez -
Learn More
Coronary Disease

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33...
Dr. Juan Manuel Pérez -
Learn More
Antithrombotic Anticoagulants

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will...
Dr. Omar Tupayachi -
Learn More
Femoral

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral...
Dr. Omar Tupayachi -
Learn More
Antithrombotic Anticoagulants

TAVR and Anticoagulation: What Should We Do?

Transcatheter aortic valve replacement (TAVR) has consolidated as a valid strategy for certain groups of patients. However,...
Dr. Carlos Fava -
Learn More